These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 3510788)

  • 21. Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide.
    Duff HJ; Roden DM; Maffucci RJ; Vesper BS; Conard GJ; Higgins SB; Oates JA; Smith RF; Woosley RL
    Am J Cardiol; 1981 Dec; 48(6):1133-40. PubMed ID: 7304461
    [No Abstract]   [Full Text] [Related]  

  • 22. Antiarrhythmic effects of flecainide against canine ventricular arrhythmias induced by two-stage coronary ligation and halothane-epinephrine.
    Dobmeyer D; Muir WW; Schaal SF
    J Cardiovasc Pharmacol; 1985; 7(2):238-44. PubMed ID: 2581074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral flecainide for suppression of ventricular arrhythmias.
    Vanhaleweyk G; Balakumaran K; Lubsen J; Roelandt J; Hugenholtz PG
    Cardiology; 1984; 71(1):30-9. PubMed ID: 6722846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man.
    Hellestrand KJ; Bexton RS; Nathan AW; Spurrell RA; Camm AJ
    Br Heart J; 1982 Aug; 48(2):140-8. PubMed ID: 7093083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Electrophysiological effects of the new antiarrhythmic drug flecainide (R 818) in man (author's transl)].
    Seipel L; Abendroth RR; Breithardt G
    Z Kardiol; 1981 Jul; 70(7):524-9. PubMed ID: 7269731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Electrophysiologic effects of flecainide acetate in patients with sinus nodal dysfunction.
    Vik-Mo H; Ohm OJ; Lund-Johansen P
    Am J Cardiol; 1982 Nov; 50(5):1090-4. PubMed ID: 7137036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Flecainide: a new antiarrhythmic agent].
    Leclercq JF; Coumel P
    Arch Mal Coeur Vaiss; 1983 Oct; 76(10):1218-30. PubMed ID: 6418100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term antiarrhythmic therapy with flecainide.
    Meinertz T; Zehender MK; Geibel A; Treese N; Hofmann T; Kasper W; Pop T
    Am J Cardiol; 1984 Jul; 54(1):91-6. PubMed ID: 6741844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical profiles of newer class I antiarrhythmic agents--tocainide, mexiletine, encainide, flecainide and lorcainide.
    Pottage A
    Am J Cardiol; 1983 Sep; 52(6):24C-31C. PubMed ID: 6414279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flecainide versus quinidine: results of a multicenter trial.
    Hodges M; Salerno DM; Granrud G
    Am J Cardiol; 1984 Feb; 53(5):66B-71B. PubMed ID: 6364770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of oral and injectable flecainide in patients with an accessory atrioventricular pathway].
    Fauchier JP; Cosnay P; Rouesnel P; Moquet B; Bonnet P; Scala PJ; Demeyer JF
    Arch Mal Coeur Vaiss; 1985 Oct; 78 Spec No():81-90. PubMed ID: 3938264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The proarrhythmic effects of flecainide.
    Nathan AW; Hellestrand KJ; Bexton RS; Spurrell RA; Camm AJ
    Drugs; 1985; 29 Suppl 4():45-53. PubMed ID: 4006779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide.
    Morganroth J; Anderson JL; Gentzkow GD
    J Am Coll Cardiol; 1986 Sep; 8(3):607-15. PubMed ID: 3745706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of flecainide acetate in the management of patients at high risk of sudden cardiac death.
    Reid PR; Griffith LS; Platia EV; Ord SE
    Am J Cardiol; 1984 Feb; 53(5):108B-111B. PubMed ID: 6695814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lorcainide (R 15 889), a first review.
    Amery WK; Heykants JJ; Xhonneux R; Towse G; Oettel P; Gough DA; Janssen PA
    Acta Cardiol; 1981; 36(3):207-34. PubMed ID: 7020313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of flecainide acetate in the treatment of premature ventricular contractions.
    Abitbol H; Califano JE; Abate C; Beilis P; Castellanos H
    Am Heart J; 1983 Feb; 105(2):227-30. PubMed ID: 6823803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical electrophysiologic study of antiarrhythmic properties of flecainide: acute intraventricular delayed conduction and prolonged repolarization in regular paced and premature beats using intracardiac monophasic action potentials with programmed stimulation.
    Olsson SB; Edvardsson N
    Am Heart J; 1981 Nov; 102(5):864-71. PubMed ID: 7304394
    [No Abstract]   [Full Text] [Related]  

  • 38. New antiarrhythmic agents.
    Pepper GA
    Nurse Pract; 1986 Jul; 11(7):62-4, 67, 70. PubMed ID: 3737022
    [No Abstract]   [Full Text] [Related]  

  • 39. Cardiac electrophysiology of four new antiarrhythmic drugs--encainide, flecainide, lorcainide and tocainide.
    Camm AJ
    Eur Heart J; 1984 Sep; 5 Suppl B():75-9. PubMed ID: 6437820
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of flecainide in the management of ventricular arrhythmias: comparative study with amiodarone.
    Dubner SJ; Elencwajg BD; Palma S; Mendelzon R; Ramos A; Bertolasi CA
    Am Heart J; 1985 Mar; 109(3 Pt 1):523-8. PubMed ID: 3883728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.